11-[5-(4-fluorophenyl)-5-oxopentyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 11-[5-(4-fluorophenyl)-5-oxopentyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole
• 英文别名: 5-(9,15-Diazatetracyclo[10.2.1.02,10.03,8]pentadeca-2(10),3,5,7-tetraen-15-yl)-1-(4-fluorophenyl)pentan-1-one
• 化学式: C₂₄H₂₅FN₂O
• 分子量: 376.474
• InChiKey: AFVUFWHJUYVTQW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  28
• 可旋转键数：
  6
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  36.1
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-溴戊腈 在 potassium carbonate 、 potassium iodide 作用下， 以 乙醚 、 N,N-二甲基甲酰胺 为溶剂， 反应 6.25h， 生成 11-[5-(4-fluorophenyl)-5-oxopentyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole
  参考文献：
  名称：

  Bridged .gamma.-carbolines and derivatives possessing selective and combined affinity for 5-HT2 and D2 receptors

  摘要：

  A series of 5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indoles and 6,7,8,9,10,11-hexahydro-7,-11-imino-5H-cyclooct[b]indoles was prepared. Structural modifications of the lead compound, 11-[4-(4-fluorobenzoyl)propyl]-5,6,7,8,9,10-hexahydro-7,10-iminocyclohept[b]indole (5, K(i) = 0.82 nM vs [H-3]ketanserin) enabled the identification of the functionality necessary for high affinity at serotonin 5-HT2 and dopamine D2 receptors in ligand binding studies. The indole ring, as well as the benzoyl or isosteric benzisoxazole moiety, were essential for high affinity. Variations of the length of the side chains resulted in ligands having either selective affinity for the 5-HT2 receptor or a combination of 5-HT2 and D2 affinity. In vivo binding studies were performed on selected members in this series. The most potent member, 2-fluoro-11-[4-(4-fluorobenzoyl)butyl]-5,6,7,8,9,-10-hexahydro-7,10-iminocyclohept[b]indole (36) had an ED50 of <1 mg/kg at the 5-HT2 and D2 receptors following oral administration.

  DOI：

  10.1021/jm00062a023

文献信息

• Sigma ligands for use in the prevention and/or treatment of postoperative pain
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2353598A1

  公开（公告）日：2011-08-10

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formulae (I), (II) or (III) to prevent and/or treat acute and chronic pain developed as a consequence of surgery, especially superficial and/or deep pain secondary to surgical tissue injury, and peripheral neuropathic pain, neuralgia, allodynia, causalgia, hyperalgesia, hyperesthesia, hyperpathia, neuritis or neuropathy secondary to surgical procedure.

  本发明涉及使用sigma配体，特别是公式（I），（II）或（III）的sigma配体，以预防和/或治疗由手术引起的急性和慢性疼痛，特别是手术组织损伤引起的表浅和/或深层疼痛，以及周围神经病理性疼痛，神经痛，触痛，烧伤性痛，痛觉过敏，疼痛过敏，神经炎或手术过程引起的神经病变。
• Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2388005A1

  公开（公告）日：2011-11-23

  The invention refers to the use of a sigma ligand, preferably a sigma ligand of formula (I), to prevent or treat emesis induced by a chemotherapeutic agent or radioactivity, especially emesis induced by taxanes, vinca alkaloids or platin chemotherapeutic drugs.

  本发明是指使用σ配体，最好是式(I)的σ配体，来预防或治疗由化疗药物或放射性诱发的呕吐，特别是由紫杉类、长春花生物碱或铂类化疗药物诱发的呕吐。
• Use of sigma ligands in opioid-induced hyperalgesia
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2415471A1

  公开（公告）日：2012-02-08

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat opioid-induced hyperalgesia (OIH) associated to opioid therapy.

  本发明是指使用σ配体，特别是式(I)的σ配体来预防和/或治疗与阿片类药物治疗相关的阿片类药物诱导的痛觉减退（OIH）。
• Use of sigma ligands in bone cancer pain
  申请人：Laboratorios del. Dr. Esteve, S.A.

  公开号：EP2460519A1

  公开（公告）日：2012-06-06

  The invention refers to the use of a sigma ligand, particularly a sigma ligand of formula (I) to prevent and/or treat pain associated to bone cancer.

  本发明是指使用σ配体，特别是式(I)的σ配体来预防和/或治疗与骨癌相关的疼痛。
• USE OF SIGMA LIGANDS IN BONE CANCER PAIN
  申请人：Laboratorios del Dr. Esteve, S.A.

  公开号：EP2646025B1

  公开（公告）日：2017-03-15